Steven Cohen Otonomy, Inc. Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.25 - $2.24 $1.37 Million - $12.3 Million	5,495,000 New	5,495,000 $1.62 Million
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.31 $1.1 Million - $1.5 Million	-648,253 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.2 $790,868 - $1.43 Million	648,253 New	648,253 $1.25 Million
Q2 2021 Aug 16, 2021	SELL	$2.06 - $2.67 $731,300 - $947,850	-355,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$2.49 - $6.23 $4.98 Million - $12.5 Million	-2,000,000 Reduced 84.93%	355,000 $905,000
Q4 2020 Feb 16, 2021	SELL	$3.48 - $6.47 $2.89 Million - $5.37 Million	-829,497 Reduced 26.05%	2,355,000 $15.2 Million
Q3 2020 Nov 16, 2020	BUY	$3.16 - $4.36 $6.98 Million - $9.64 Million	2,210,238 Added 226.86%	3,184,497 $12.9 Million
Q2 2020 Aug 14, 2020	BUY	$1.87 - $3.84 $1.45 Million - $2.97 Million	774,259 Added 387.13%	974,259 $3.53 Million
Q1 2020 May 15, 2020	BUY	$1.58 - $4.06 $316,000 - $811,999	200,000 New	200,000 $394,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.